Lactococcus lactis JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial

Shibata, Takeo; Kanayama, Masaya; Haida, Munetaka; Fujimoto, Shuhei; Oroguchi, Takashige; Sata, Kenji; Mita, Nobutaka; Kutsuzawa, Tomoko; Ikeuchi, Mayumi; Kondo, Masaru; Naito, Kimitoshi; Tsuda, Michio; Nishizaki, Yasuhiro; Ishii, Naoaki

doi:10.1016/j.jff.2016.03.035

Cited by 32 publications

(36 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The severity of each symptom was scored using 5 grades. Evaluation of influenza and URTI incidence was performed from the severity of symptoms according to a previously reported diagnostic criterion list [ 25 ]. Measurements of severity of each symptoms were performed according to a previous report [ 28 ].…”

Section: Methodsmentioning

confidence: 99%

“…LC-Plasma yogurt intake for 4 weeks activated maturation markers of pDC and intake for 12 weeks reduced the cumulative number of incidence days of influenza-like symptoms [ 23 , 24 ]. In addition, heat-killed LC-Plasma supplementation for 12 weeks reduced the number of incidence days of symptoms related to URTI [ 25 ]. However, there is no report regarding the efficacy of LC-Plasma supplementation on pDC activation in athletes under HIE.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of heat-killed Lactococcus lactis JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial

Komano

Shimada

Naito

et al. 2018

Journal of the International Society of Sports Nutrition

View full text Add to dashboard Cite

BackgroundLactococcus lactis JCM 5805 (LC-Plasma) is a unique lactic acid bacteria (LAB) which activates plasmacytoid dendritic cells (pDC). We aimed to evaluate the effect of LC-Plasma on dendritic cell (DC) activity and subjective indices of upper respiratory tract infections (URTI) and fatigue in athletes under high intensity exercise.MethodsWe conducted a randomized, placebo-controlled, double-blinded trial. Fifty-one male subjects belonging to a university sports club were randomized into placebo (n = 25) and LC-Plasma (n = 26) groups. Individuals ingested placebo capsules containing cornstarch or LC-Plasma capsules containing 100 billion cells of heat-killed LC-Plasma per day for 13 days. During the intervention period, subjects performed high intensity exercise according to their sports club training regime. Blood and saliva sampling were obtained at days 1 and 14, and physical conditions were recorded in a diary. We investigated expression of maturation markers on DCs, muscle damage and stress markers and used student’s t test adjusted by Bonferoni’s method for multiple comparison between groups. These data were presented as mean ± SD. We also investigated cumulative days of symptoms regarding infections and fatigue and used Chi-square test for comparison between groups. These data were presented as cumulative number.ResultsCD86 as maturation marker on pDC was significantly increased in the LC-Plasma group at day 14 (Placebo: 296 ± 70 vs. LC-Plasma: 365 ± 115; Mean Fluorescent Intensity; p = 0.013). Cumulative days of URTI were significantly lower in the LC-Plasma group (Placebo: URTI positive 56, URTI negative 256 vs. LC-Plasma: URTI positive 39, URTI negative 299; days; p = 0.028) and symptoms like sneeze or running nose were significantly lower in the LC-Plasma group (Placebo: Symptom positive 52, Symptom negative 258, vs. LC-Plasma: Symptom positive 36, Symptom negative 301; days; p = 0.032). Moreover, the cumulative days of fatigue were significantly fewer in the LC-Plasma group (Placebo: Symptom positive 128, Symptom negative 182, vs. LC-Plasma: Symptom positive 110, Symptom negative 225; days; p = 0.032). Markers of muscle damage and stress markers were not significantly different between groups.ConclusionWe consider that heat-killed LC-Plasma supplementation relieves morbidity and symptoms of URTI via activation of pDC and decreases fatigue accumulation during consecutive high intensity exercise in athletes. However, LC-Plasma ingestion did not affect markers of muscle damage and stress.Trial registrationUMIN-CTR, UMIN000020372. Registered 28 December 2015.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of heat-killed Lactococcus lactis JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial

Komano

Shimada

Naito

et al. 2018

Journal of the International Society of Sports Nutrition

View full text Add to dashboard Cite

show abstract

“…The prophylactic effects of L. lactis JCM5805 on influenza-like illness in healthy volunteers during the winter season were reported based on the results of a double-blinded trial [ 56 , 57 ]. The administration of L. lactis JCM5805 resulted in a significant decrease in the cumulative number of days of incidence of “cough” and “feverishness”, which were defined as the major symptoms of an influenza-like illness, as compared with the control group.…”

Section: Prophylaxis and Medical Treatment Of Infectious Diseases By mentioning

confidence: 99%

“…These results suggest that the intake of L. lactis JCM5805 can prevent the pathogenesis of an influenza-like illness via the enhancement of an IFN-α-mediated response to the influenza virus [ 56 ]. In two separate studies, the expression of IFN-α and the mRNA level of ISG15 in PBMCs were significantly higher in groups treated with L. lactis JCM 5805 as compared to the corresponding control groups [ 57 , 58 ]. In addition, Sakata et al .…”

Section: Prophylaxis and Medical Treatment Of Infectious Diseases By mentioning

confidence: 99%

Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems

Kanauchi

Andoh

AbuBakar

et al. 2018

CPD

154

124

View full text Add to dashboard Cite

Recently, the risk of viral infection has dramatically increased owing to changes in human ecology such as global warming and an increased geographical movement of people and goods. Howev-er, the efficacy of vaccines and remedies for infectious diseases is limited by the high mutation rates of viruses, especially, RNA viruses. Here, we comprehensively review the effectiveness of several probiot-ics and paraprobiotics (sterilized probiotics) for the prevention or treatment of virally-induced infectious diseases. We discuss the unique roles of these agents in modulating the cross-talk between commensal bacteria and the mucosal immune system. In addition, we provide an overview of the unique mechanism by which viruses are eliminated through the stimulation of type 1 interferon production by probiotics and paraprobiotics via the activation of dendritic cells. Although further detailed research is necessary in the future, probiotics and/or paraprobiotics are expected to be among the rational adjunctive options for the treatment of various viral diseases.

show abstract

“…Additionally, the oral administration of LC-Plasma strongly decreased pathogenesis in a murine parainfluenza virus infection model 12 . In some clinical studies, the intake of yogurt or supplements containing LC-Plasma has been reported to affect the activity of human pDCs and mitigate the symptoms of flu and common cold without adverse effects 13 – 15 . Hence, the activation of pDCs by LAB seems to be beneficial to defend against viral infection.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate

Kanayama

Kato

Tsuji

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

Plasmacytoid dendritic cells (pDCs) play a key role in the immune response against viruses. In addition, recent research has suggested that pDCs possess direct and indirect tumoricidal activities. We previously found that a lactic acid bacteria strain, Lactococcus lactis JCM 5805 (LC-Plasma), stimulated pDCs and prevented viral infection in mouse and human studies. Meanwhile, emulsifiers have recently been highlighted as candidate adjuvants for some viral vaccines and cancer immunotherapies. In this study, we discovered some specific emulsifiers, mainly consisting of sucrose fatty acid esters, that drastically enhance the potency of LC-Plasma to activate pDCs in vitro. The emulsifiers promoted the efficient uptake of LC-Plasma by pDCs and the ratio of pDCs that took up LC-Plasma correlated with the activity of pDCs. In addition, an in vivo study showed that oral treatment with LC-Plasma mixed with an emulsifier induced a higher expression of genes related to anti-viral immunity in the lung compared to treatment with LC-Plasma alone. Both LC-Plasma and the emulsifiers used in this study have been confirmed to be safe for human use. Therefore, LC-Plasma mixed with an emulsifier might be a useful tool for certain anti-cancer and anti-viral therapies.

show abstract

Lactococcus lactis JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial

Cited by 32 publications

References 32 publications

Efficacy of heat-killed Lactococcus lactis JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial

Efficacy of heat-killed Lactococcus lactis JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial

Probiotics and Paraprobiotics in Viral Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems

Enhancement of immunomodulative effect of lactic acid bacteria on plasmacytoid dendritic cells with sucrose palmitate

Contact Info

Product

Resources

About